FibroBiologics, Inc.
corporate_fare Company Profile
FibroBiologics, Inc. (NASDAQ:FBLG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for FBLG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-08, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 12 rated 8 or above. Recent SEC coverage for FBLG spans 8-K, SCHEDULE 13D, 10-Q, DEF 14A.
Recent high-impact activity:
- FibroBiologics Sells $1.2M Convertible Debenture at 15% Discount to Peak One
- CSO Invests $0.5M in New Private Placement as Stockholders Approve Warrant Share Issuance
- CSO Hamid Khoja Buys $0.5M in FibroBiologics Private Placement at $1.675/Share
- CSO's $0.5M Private Placement Signals Insider Confidence Amid Nasdaq Delisting Battle
- FibroBiologics Wins U.S. Patent for Fibroblast Tech to Boost Islet Transplant Survival
Financial Snapshot
Short Interest & Short Volume
3.12 days to coverFINRA reported short interest of 334,123 shares in FBLG as of the October 30, 2026 settlement, a 1.1% increase from the prior period — about 3.1 days to cover at its recent average daily volume. On November 19, 2026, 70.3% of FBLG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for FBLG, detected from its recent SEC filings · based on capital-structure filings through 2026-07-31.
Proxy Seeks Approval for 8.4M Warrant Shares · Dilution Would Exceed 50% of Current Outstanding
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →